InvestorLens

GILD — GILEAD SCIENCES INC

Health Care · Drug Manufacturers

Sign in to save5 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying GILD?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
75
Institutional Conviction
Mixed · 3 buying vs 1 selling last quarter
51
Macro Tailwind
Macro conditions are mixed for this sector
53
Congressional Activity
2 congressional purchases, 0 sales disclosed in the last 6 months
Why? — Evidence & Confidence ▾

Of 4 tracked investors who changed their GILD position last quarter, 3 bought and 1 sold (75% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 53/100 in a Overheat regime). 2 congressional purchases, 0 sales disclosed in the last 6 months.

Supporting evidence
  • +3 tracked investors added or increased positions last quarter (Ray Dalio, Steve Cohen, Paul Tudor Jones)
  • +5 tracked investors reported holding GILD at their latest filing
  • +2 congressional purchases disclosed in the last 6 months
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About GILEAD SCIENCES INC (GILD)

GILEAD SCIENCES INC (GILD) appears in the most recent 13F filings of 5 tracked institutional investors. GILEAD SCIENCES INC is classified in the Health Care sector (Drug Manufacturers industry). The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $958M. Across recent filings, tracked investors recorded 5 new positions, 15 increased, 10 reduced, and 2 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in GILD

63
/100
Institutional Accumulation
Added / Increased20
Reduced10
Exited2
BearishBullish
Crowded Trade Score™

How many top investors track GILD

33
/100
Emerging Interest
5investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

GILD Ownership Composition

How GILEAD SCIENCES INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
94% of tracked value
Institutions
5
tracked investors
Total Reported
$1.2B
combined 13F value
Types2
  • Multi-Strategy / Quant93.9%
  • Macro6.1%
Multi-Strategy / Quant(3)
93.9%
Macro(2)
6.1%

Tracked investors currently reporting GILD

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    5.6M
    Value
    $704.5M
    % Portfolio
    0.08%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    2.2M
    Value
    $275.4M
    % Portfolio
    0.10%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    1.5M
    Value
    $186.9M
    % Portfolio
    0.21%
  • Ray DalioJun 30, 2026
    Bridgewater Associates
    Shares
    290.9K
    Value
    $36.7M
    % Portfolio
    0.15%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    306.5K
    Value
    $38.7M
    % Portfolio
    0.05%

Recent activity

Frequently asked questions

How many institutional investors hold GILD?
5 tracked institutional investors disclosed a position in GILD (GILEAD SCIENCES INC) in their most recent 13F filing.
Who is the largest institutional holder of GILD?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in GILD, valued at $958M.
Did institutional ownership of GILD increase or decrease?
Across recent 13F filings, tracked investors recorded 5 new positions, 15 increased, 10 reduced, and 2 fully exited GILD.
What sector is GILD in?
GILEAD SCIENCES INC is classified in the Health Care GICS sector, Drug Manufacturers industry.
Where does this GILD ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.